MEOBF MESOBLAST LTD
BULLISH
Impact: 6/10
6-K
Notable filing: 6-K
Latest settled — T+20d
MEOBF ▲ +6.25% at T+20d
LONG call ✓ call won +6.25% · α vs SPY +0.21% · entry $1.60 → $1.70
Currently $1.55 · -3.13% from $1.60 entry
T+1d
0.00%
call 0.00% · α -0.25%
$1.60
settled 8w ago
T+5d
+6.25%
call +6.25% · α +4.61%
$1.70
settled 7w ago
T+20d
+6.25%
call +6.25% · α +0.21%
$1.70
settled 4w ago
T+60d
—
call — · α —
—
in 27d
Price Chart
Loading chart...
Executive Summary
Mesoblast Limited has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform from Mayo Clinic, enhancing its mesenchymal lineage stromal cell (MSC) products. The acquisition was made through the issuance of ASX ordinary shares.
Actionable Insight
The acquisition of CAR technology could significantly enhance Mesoblast's product pipeline and competitive position in cell therapies, though the share issuance may lead to dilution.
Key Facts
- Acquired exclusive worldwide license to patented CAR technology platform
- Technology aims to enhance targeting and potency of MSC products
- Acquisition accomplished through issuance of ASX ordinary shares
- Mayo Clinic will provide in-kind support for technology advancement
- Potential applications include ulcerative colitis, Crohn's disease, and lupus nephritis
Financial Impact
Acquisition made through issuance of ASX ordinary shares
dilutionintellectual_property
Risk Factors
- Dilution from issuance of new shares
- Uncertainty in successful integration and commercialization of the technology
- Dependence on Mayo Clinic's in-kind support
Market Snapshot
Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000047 |
| Exhibit: exhibit991caracquisition.htm | 0001345099-26-000047 |
| Document: 0001345099-26-000047-index-headers.html | 0001345099-26-000047 |
| Document: 0001345099-26-000047-index.html | 0001345099-26-000047 |
| Document: 0001345099-26-000047.txt | 0001345099-26-000047 |
8 reports for MEOBF
75%
Hit rate
best @ T+20▲ +6.25%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
2d ago
|
6-K
| $1.70 awaiting T+20 | awaiting T+20 | — | $1.55 (−8.82%) |
|
Apr 30, 2026
6w ago
|
6-K
| $1.70 $1.70 | · 0.00% | ▼ −5.23% | $1.55 (−8.82%) |
|
Apr 17, 2026
8w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▲ +0.88% | $1.55 (−3.13%) |
|
Apr 15, 2026
8w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▲ +0.21% | $1.55 (−3.13%) |
|
Apr 8, 2026
9w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.55 (−3.13%) |
|
Apr 8, 2026
9w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.55 (−3.13%) |
|
Apr 8, 2026
9w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.55 (−3.13%) |
|
Apr 8, 2026
9w ago
|
6-K
| $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.55 (−3.13%) |
Showing 8 of 8
US Market Status
Market Closed — Opens Mon (48h 48m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access